TABLE 1.
Baseline characteristics of study participantsa
| Bacterial etiology (n = 36) | Viral etiology (n = 27) | SARS-CoV-2 (n = 22) | Mixed bacterial–viral etiology (n = 38) | |
|---|---|---|---|---|
| Age in years (median with IQR) | 73 (60.5–78) | 66 (52–74.5) | 58.5 (47–76.8) | 68 (52.5–80.0) |
| Female (%) | 17 (47.2) | 16 (59.3) | 6 (27.3) | 25 (65.8) |
| Patients diagnosed with LRTIs | ||||
| Confirmed CAPb (%) | 36 (100.0) | 5 (18.5) | 15 (68.2) | 36 (94.7) |
| Other respiratory tract infections (%) | 0 (0.0) | 15 (55.5) | 6 (27.3) | 2 (5.2) |
| Infectious exacerbation of COPD (%) | 0 (0.0) | 7 (25.9) | 1 (4.5) | 0 (0.0) |
| Laboratory findings | ||||
| C-reactive protein (mg/L; median with IQR) | 141 (69–258.3) | 38 (22.5–57.5) | 62.5 (27.8–131.5) | 180.0 (108–245) |
| Procalcitonin (µg/L; median with IQR) | 0.2 (0.8–0.44) | 0.01 (0.0–0.23) | 0.19 (0.0–0.46) | 0.28 (0.15–0.74) |
| Antibiotic usage | ||||
| Antibiotics not given or if given ≤8 hours (%) | 0 (0.0) | 10 (37.0) | 15 (68.2) | 0 (0.0) |
a
IQR, interquartile range; COPD, chronic obstructive pulmonary disease.
b
Clinically confirmed CAP, of which 75 out of 92 were radiologically confirmed cases.